Sagent Pharmaceuticals, Inc., a specialty pharmaceutical company has launched Vancomycin hydrochloride for injection, USP, an anti-infective, in a 10 gram preservative-free pharmacy bulk package presentation.
The Vancomycin 10 gram presentation is an addition to Sagent's Vancomycin 5 gram pharmacy bulk package offering. For the 12 months ending February 2015, the US market for Vancomycin approximated $196 million of which over 50% of the sales was pharmacy bulk package bottles. As with all products in Sagent's portfolio, Vancomycin features Sagent's PreventIV MeasuresSM packaging and labeling, designed to help reduce medication errors.
Vancomycin hydrochloride for injection, USP is indicated for the treatment of serious or severe infections caused by susceptible strains of methicillin-resistant (ß-lactam-resistant) staphylococci. To reduce the development of drug-resistant bacteria and maintain the effectiveness of vancomycin and other antibacterial drugs, vancomycin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. It is indicated for penicillin-allergic patients, for patients who cannot receive or who have failed to respond to other drugs, including the penicillins or cephalosporins, and for infections caused by vancomycin-susceptible organisms that are resistant to other antimicrobial drugs.
Sagent Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, sources, manufactures, and markets pharmaceutical products, principally injectable-based generic equivalents to branded products in North America. Sagent Pharmaceuticals, Inc. was founded in 2006 and is headquartered in Schaumburg, Illinois.
Subscribe to PharmaTutor News Alerts by Email >>
